Resources
Blog: Read the latest post
5 insights from JPM 2025
January 29, 2025
Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface.
Webinar: Watch on-demand
Watch this webinar with Alok Tayi, PhD, Founder and CEO of Vibe Bio, to learn on how AI is accelerating the business development process, helping executive teams move faster by making it easier to collect, manage, access, and evaluate drug assets, thus empowering them to conduct more thorough due diligence with the same resources.
Additional resources
Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface.
By combining human expertise with AI-powered analysis, we're helping biopharma companies make faster, more informed business development decisions.
Artificial intelligence-powered pipeline analysis is emerging as a tool that can help teams make better, faster drug development decisions.
Implementing guardrails for artificial intelligence (AI) in the biopharmaceutical industry is crucial for ensuring effective, safe, and compliant use of this powerful technology.
Limited Partners (LPs) are at the heart of the biotech funding ecosystem—these crucial players ignite the funding flywheel that drives biotech innovation.
Let’s explore the four most common use cases for an AI-powered drug pipeline analysis platform and how they support strategic decision-making in biopharma.
Uncover new possibilities with VibeOne
Learn how VibeOne can help you discover your next indication or identify high potential development opportunities in your portfolio.
